New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Please provide your email address to receive an email when new articles are posted on . Beta-blockers more effectively reduce risk for death or hospitalization in people with HFpEF compared with ...

Aisa Pharma has reported positive results from its Phase II RECONNOITER trial of AISA-021 (cilnidipine), a once-daily calcium channel blocker, for patients with systemic sclerosis-associated Raynaud’s ...

Myotonic dystrophy is one of the most common forms of muscular dystrophy. It is a genetic condition that causes progressive muscle weakness and wasting. No treatments currently exist that slow the ...

Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 23, entitled, “Benidipine calcium channel blocker ...

Findings provide reassurance to physicians and patients about the long-term safety of dihydropyridine calcium channel blockers in the treatment of pancreatic cancer. This was a new user, active ...

A woman with hopes to conceive was diagnosed with severe vasospastic angina (VSA); however, she was able to carry a healthy baby to full term without angina attacks after starting treatment of a ...